The Ipsos survey of 1,078 adults found 24% of people would use weight-loss jabs if they were provided for free by the health ...

每经记者 许立波    每经编辑 梁枭     丨 2024年11月19日 星期二 丨NO.1 ...

中药公司康缘药业因关联并购事项备受关注。康缘药业近日发布公告称，公司拟以自有资金2.7亿元收购控股股东旗下的江苏中新医药有限公司（简称“中新医药”）股权。据悉，目前中新医药4个创新药的6个临床批件均进入临床阶段，其中包括两条GLP-1药物管线。

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound, according to the AXIACI ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The ...

Ozempic is a medicine used to treat type 2 diabetes. It helps with weight loss by reducing appetite. Some foods have similar ...

Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

Skipping your dose to over-indulge could leave you “excusing yourself from the table in a hurry,” an expert tells PEOPLE ...